Call for Papers: Use of Radiopharmaceuticals
Robert C. Miller, MD, FASTRO and William Small Jr., MD, FASTRO
The Advances editors are delighted to announce that in 2021 we will have a special edition looking at the use of radiopharmaceuticals. Radiopharmaceutical therapy is emerging as a safe and effective targeted approach to treating many types of cancer. Novel therapeutic radiopharmaceuticals are being developed at an impressive rate and are intended to tackle both the diagnosis and treatment of a disease with a single agent. Radiopharmaceutical dosimetry is also currently in its infancy but has the potential to transform the field in the same way it did for external beam radiation therapy.
We feel that this subject is very timely and of critical importance for our specialty, and are calling for original scientific studies, clinical trials, review articles, and opinion pieces on its many aspects. We have a call for papers that includes the following categories:
- PSMA or Ga 68 PSMA11 or Prostate specific membrane antigen
- Clinical Trials of new agents
- Single time point dosimetry or individualized dosimetry
- Patient selection
- Training and experience requirements for authorized users
- Radiation Oncologist role in radiopharmaceuticals
Our deadline for manuscript submission is June 30, 2022. To submit, please send papers through the journal’s submission system and select “Radiopharmaceuticals” as the article type. If past evidence is a good guide, we do anticipate an excellent response. Thanks in advance to all of you who submit manuscripts, and we are looking forward to an excellent special edition of the journal. Please reach out to the editorial office with any questions at [email protected].